GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Gain Therapeutics Inc.
Gain Therapeutics, a biotech company using a computational drug discovery platform, is a bet on its scientific approach. Its price trajectory depends on news from preclinical and early clinical trials.
Share prices of companies in the market segment - Treatment
Gain Therapeutics uses its proprietary platform to identify and develop small-molecule drugs that can restore the function of misfolded proteins in rare genetic and neurodegenerative diseases. We've classified it in the "Treatment" segment. The chart below shows the overall dynamics of this innovative biotech sector.
Broad Market Index - GURU.Markets
Gain Therapeutics is a biopharmaceutical company that uses its technology platform to discover new drugs for the treatment of rare genetic and neurodegenerative diseases. It is a component of the GURU.Markets index. The chart below shows the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
GANX - Daily change in the company's share price Gain Therapeutics Inc.
For Gain Therapeutics, Inc., a company developing drugs for rare diseases, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to preclinical and clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Treatment
Gain Therapeutics, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with GANX, which focuses on rare disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Gain Therapeutics is a biotech company working on treatments for genetic diseases. Its shares represent a venture bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Gain Therapeutics Inc.
Gain Therapeutics, Inc.'s year-over-year performance tells the story of its unique drug discovery platform. Its 12-month market cap depends entirely on progress in preclinical studies, where it must prove that its computational approach can identify previously hidden allosteric sites on proteins to create targeted therapies.
Annual dynamics of market capitalization of the market segment - Treatment
Gain Therapeutics, Inc. is an early-stage biotech company leveraging its platform to discover new drugs. Its stock performance is entirely dependent on the results of preclinical and clinical trials. The chart reflects the high risk and speculative nature of this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gain Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Gain Therapeutics Inc.
Gain Therapeutics is a biotech company using its proprietary drug discovery platform. Being an early-stage company, its monthly valuation is based on scientific potential. Progress in preclinical studies and partnership announcements are its primary drivers.
Monthly dynamics of market capitalization of the market segment - Treatment
Biotechnology, which focuses on finding cures for rare genetic and neurodegenerative diseases, is a high-risk field. The dynamics of this sector, shown in the chart, reflect its volatility. Companies like Gain Therapeutics are conducting their research in this knowledge-intensive environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gain Therapeutics, a biopharmaceutical company, lives by the laws of science. Its stock price depends on research results, not market cycles. Its performance is completely disconnected from general economic trends, betting on scientific breakthroughs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Gain Therapeutics Inc.
Gain Therapeutics, an early-stage biotech, is experiencing extremely volatile weekly performance. News about the progress of its drug discovery platform, particularly in the field of neurodegenerative diseases, could trigger sharp speculative moves.
Weekly dynamics of market capitalization of the market segment - Treatment
Gain Therapeutics and the entire early-stage biotech sector are driven by a common backdrop of investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire niche. The chart shows how the company's stock reacts to this shared "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Gain Therapeutics and the entire early-stage biotech sector are driven by a common backdrop of investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire niche. The chart shows how the company's stock reacts to this shared "noise."
Market capitalization of the company, segment and market as a whole
GANX - Market capitalization of the company Gain Therapeutics Inc.
Gain Therapeutics' market cap is the financial valuation of a biotech company using its platform to discover new drugs for rare genetic and neurodegenerative diseases. The chart reflects investor expectations for its technology. Its speculative dynamics tell the story of how the market evaluates preclinical science.
GANX - Share of the company's market capitalization Gain Therapeutics Inc. within the market segment - Treatment
Gain Therapeutics is a biotech company using its proprietary platform to discover new drugs aimed at restoring the proper function of misfolded proteins. Its market share reflects the potential of its innovative approach to treating rare genetic and neurodegenerative diseases.
Market capitalization of the market segment - Treatment
Gain Therapeutics uses its technology platform to discover new drugs for rare genetic and neurodegenerative diseases. The chart below shows the overall market capitalization of the entire sector. Its dynamics reflect the hopes that AI and big data will accelerate drug development.
Market capitalization of all companies included in a broad market index - GURU.Markets
Drug development, as seen in the chart, is exploring new approaches. Gain Therapeutics is using its technology platform to discover molecules that can correct misfolded proteins. Its capitalization represents a risky bet on this innovative technology for treating rare genetic diseases.
Book value capitalization of the company, segment and market as a whole
GANX - Book value capitalization of the company Gain Therapeutics Inc.
Gain Therapeutics' book value is capital used to fight diseases caused by protein misfolding. Currently in the R&D stage, the company is using its financial assets to develop drugs that could help treat conditions such as Parkinson's disease.
GANX - Share of the company's book capitalization Gain Therapeutics Inc. within the market segment - Treatment
Gain Therapeutics, a biotech company, uses its platform to discover new drugs. Its share of the sector's assets consists of R&D laboratories. Currently, the company is building a scientific and intellectual base that will serve as the foundation for its future drugs.
Market segment balance sheet capitalization - Treatment
Gain Therapeutics, Inc. is a biotech company, which accounts for its low capital intensity. Its value lies in its drug discovery platform, not its manufacturing facilities. Compared to the pharmaceutical sector, its "light" balance sheet is typical for companies in preclinical and early clinical development.
Book value of all companies included in the broad market index - GURU.Markets
Gain Therapeutics' assets are not drugs, but a unique computational platform that allows the discovery of previously hidden active sites on proteins to create new drugs. The company's balance sheet reflects the value of this innovative technology. The chart shows how much capital is invested in this new drug discovery method.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Gain Therapeutics Inc.
Gain Therapeutics is a biotech company that uses supercomputers to discover new drugs. Its market value is derived from the valuation of its innovative computing platform. Investors are betting on its ability to speed up and reduce the cost of drug development.
Market to book capitalization ratio in a market segment - Treatment
Gain Therapeutics uses its technology platform to discover new drugs for rare genetic and neurodegenerative diseases. Its value is the potential of this platform. This chart shows how investor expectations for its science shape its valuation, separate from the value of its physical assets.
Market to book capitalization ratio for the market as a whole
Gain Therapeutics is a biotech company using its proprietary drug discovery platform. Its market capitalization is based on the potential of this technology. The chart shows the significant premium investors pay for an innovative scientific platform capable of accelerating drug development compared to its tangible assets.
Debts of the company, segment and market as a whole
GANX - Company debts Gain Therapeutics Inc.
Gain Therapeutics uses its technology platform to discover new drugs for rare genetic diseases. This process requires significant investment in computational biology and laboratory research. Debt financing could provide the company with the resources to advance its developments to the preclinical stage.
Market segment debts - Treatment
Gain Therapeutics is a preclinical-stage biotech company using its platform to discover new drugs. Funding at this very early stage is almost exclusively equity. This chart shows whether the company is following this standard biotech financial model to validate its scientific hypotheses and advance its developments to clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Gain Therapeutics Inc.
Gain Therapeutics, a biopharmaceutical company seeking new treatments for rare diseases, is in the research phase. This chart illustrates its reliance on external funding. Taking on debt to cover massive R&D costs is a gamble. Success will bring huge profits, while failure could lead to bankruptcy.
Market segment debt to market segment book capitalization - Treatment
Gain Therapeutics uses its technology platform to discover new drugs for rare genetic and neurodegenerative diseases. This chart compares the debt raised for this high-tech research to the overall market capitalization of the entire sector. It reflects the financial implications of using advanced computing in pharmaceuticals.
Debt to book value of all companies in the market
Gain Therapeutics develops drugs to treat genetic diseases. This requires long-term and risky investments. The chart shows how the company finances its research. Comparisons with the biotech sector help investors assess the company's stage and the financial risks involved in developing a cure.
P/E of the company, segment and market as a whole
P/E - Gain Therapeutics Inc.
This chart for Gain Therapeutics, a biopharmaceutical company using supercomputers to discover new drugs, is a bet on a technological approach. Investors have a very high estimate of its potential profit, as they believe in the effectiveness of its platform. The momentum reflects progress in research and the belief that AI can accelerate drug discovery.
P/E of the market segment - Treatment
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Gain Therapeutics. For investors, it serves as a benchmark, indicating the overall level of optimism. Against this backdrop, one can gauge expectations for the company's unique drug discovery platform and its chances of success.
P/E of the market as a whole
Gain Therapeutics uses its technology platform to discover new drugs for rare genetic and neurodegenerative diseases. The company aims to discover previously inaccessible drug targets. This chart shows the sentiment in the biotech sector, providing insight into how the market views the potential of this innovative drug discovery platform and its scientific prospects.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Gain Therapeutics Inc.
Gain Therapeutics is a biotech company using its platform to identify novel molecules capable of treating diseases caused by protein misfolding. This chart reflects analysts' confidence in its computational approach to drug discovery and is an indicator of expectations for its preclinical and clinical programs.
%20P%2FE%20Gain%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Gain-Therapeutics-Inc.&v=1772647243329 "Chart of the company's future (projected) P/E Gain Therapeutics Inc.")
Future (projected) P/E of the market segment - Treatment
Gain Therapeutics uses its proprietary computational platform to identify new molecules that can correct misfolded proteins that cause disease. This chart shows how its profitability expectations compare to the biotech sector, reflecting the level of investor confidence in its technological approach to drug discovery.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Treatment&v=1772647243369 "Future (projected) P/E graph of the market segment - Treatment")
Future (projected) P/E of the market as a whole
Gain Therapeutics is a biotech company using its platform to discover new drugs for rare diseases. This chart shows the company's overall risk appetite. Gain's success depends on the ability of its technology to identify effective molecules. A positive market environment helps with funding, but it cannot replace a scientific breakthrough.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772647243379 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Gain Therapeutics Inc.
Gain Therapeutics is a biotech company using its platform to discover new drugs aimed at restoring the proper function of misfolded proteins. This chart shows the company's financial progress during preclinical development. Current results reflect the investment in this innovative technology.
Profit of companies in the market segment - Treatment
Gain Therapeutics is a biotech company using its platform to identify new molecules capable of treating diseases caused by protein misfolding, particularly Parkinson's disease. This chart shows the overall financial picture of the biotech sector, reflecting expectations for new approaches to treating complex neurodegenerative diseases.
Overall market profit
Gain Therapeutics is a biotech company using its proprietary platform to discover new drugs. Its value is determined by the potential of its scientific developments. The company's prospects lie in the realm of science and medicine and are not dependent on short-term economic fluctuations. However, the investment climate in the industry is dependent on overall market sentiment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Gain Therapeutics Inc.
Gain Therapeutics uses its technology platform to discover new drugs for rare genetic and neurodegenerative diseases. It is an early-stage research company. Its revenue projections are long-term models based on analysts' confidence in the potential of its scientific platform.
%20profit%20of%20the%20company%20Gain%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Gain-Therapeutics-Inc.&v=1772647243641 "Graph of future (projected) profit of the company Gain Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Treatment
Gain Therapeutics uses its proprietary technology to discover new drugs aimed at restoring the function of misfolded proteins. This chart shows forecasts for the biotech sector. The company's future profitability depends on the success of its innovative platform for developing drugs to treat rare genetic and neurodegenerative diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Treatment&v=1772647243665 "Graph of future (predicted) profits of companies in a market segment - Treatment")
Future (predicted) profit of the market as a whole
Gain Therapeutics develops drugs for rare genetic diseases. Funding such research requires long-term investment and a high risk appetite on the part of investors. This chart, illustrating overall profit expectations, demonstrates how favorable the investment climate is for capital-intensive and innovative biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772647243679 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Gain Therapeutics Inc.
Gain Therapeutics is a biotech company using its platform to discover new drugs aimed at restoring the function of misfolded proteins. This chart reflects an assessment of its scientific potential. It shows investor expectations for a breakthrough in the treatment of diseases caused by protein folding errors.
P/S market segment - Treatment
Gain Therapeutics is a biopharmaceutical company using its AI-powered platform to discover new drugs aimed at restoring the function of misfolded proteins. This approach is applicable to rare and neurodegenerative diseases. This chart shows the average biotech valuation, which helps understand how the market values Gain's innovative technology platform.
P/S of the market as a whole
Gain Therapeutics uses its proprietary technology platform to discover new drugs for the treatment of rare genetic and neurodegenerative diseases. This revenue valuation indicator emphasizes that investors evaluate not current sales, but the scientific potential of the company's platform and the likelihood of future success of its developments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Gain Therapeutics Inc.
Gain Therapeutics develops drugs to treat rare genetic and neurodegenerative diseases using its platform to identify new therapeutic targets. This chart reflects investors' confidence in the potential of this technology. The valuation is based on future revenues contingent on successful clinical trials.
%20P%2FS%20Gain%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Gain-Therapeutics-Inc.&v=1772647243758 "The graph of the company's future (projected) P/S Gain Therapeutics Inc.")
Future (projected) P/S of the market segment - Treatment
Gain Therapeutics is a biotech company using its platform to discover new drugs for the treatment of rare genetic and neurodegenerative diseases. This chart compares the company's future revenue expectations with its industry. It reflects investor confidence in its technology and the potential of its developments.
%20P%2FS%20market%20segment%20graph%20-%20Treatment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Treatment&v=1772647243811 "Future (projected) P/S market segment graph - Treatment")
Future (projected) P/S of the market as a whole
Gain Therapeutics is a biopharmaceutical company using its proprietary technology platform to discover new drugs targeting misfolded proteins. This graph reflects confidence in future growth, as Gain is working on a fundamentally new approach to treatment. The success of its platform could lead to the development of drugs for a wide range of diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772647243832 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Gain Therapeutics Inc.
Gain Therapeutics is a preclinical biopharmaceutical company using its proprietary drug discovery platform. Currently, the company has no commercial sales revenue. Any revenue reflected in this chart likely comes from grants or early partnerships.
Sales of companies in the market segment - Treatment
Gain Therapeutics is a biotech company using its proprietary platform to discover new drugs that can correct protein misfolding that causes disease. This graph reflects the dynamics of the pharmaceutical sector, where innovative approaches to drug discovery can significantly accelerate the development of new therapies.
Overall market sales
Gain Therapeutics, Inc. uses its proprietary platform to discover new drugs for rare genetic and neurodegenerative diseases. Its activities are funded by venture capital. The growth in total economic revenue, reflected in this chart, improves the investment climate, making it easier for companies like Gain to raise funds for expensive and long-term research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Gain Therapeutics Inc.
Gain Therapeutics, Inc. is a biopharmaceutical company using its platform to discover new drugs aimed at restoring the function of misfolded proteins in rare genetic and neurodegenerative diseases. This chart reflects analyst expectations for the company's research progress and the potential of its platform.
%20sales%20of%20the%20company%20Gain%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Gain-Therapeutics-Inc.&v=1772647243961 "Schedule of future (projected) sales of the company Gain Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Treatment
Gain Therapeutics uses its proprietary platform to discover new drugs aimed at restoring protein function in rare genetic and neurodegenerative diseases. This chart shows healthcare projections, helping to understand the potential of Gain's innovative approach to developing new treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Treatment&v=1772647244054 "Schedule of future (projected) sales of companies in the market segment - Treatment")
Future (projected) sales of the market as a whole
Gain Therapeutics, a biopharmaceutical company, sees this chart as an indicator of the overall health of the investment market. Developing new drugs requires significant capital, and the positive economic outlook reflected here increases investor willingness to fund long-term, risky, but promising scientific research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772647244076 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Gain Therapeutics Inc.
Gain Therapeutics is a preclinical biotechnology company using its platform to discover new drugs. At this stage, its activities are entirely focused on research. This chart illustrates the financial side of this process, showing the investment required to test scientific hypotheses and develop potential drug candidates.
Market segment marginality - Treatment
Gain Therapeutics uses its technology platform to discover new drugs targeting misfolded proteins. For a biotech platform, efficiency is defined as the speed and accuracy of identifying promising molecules. The graph demonstrates how cost-effective the company's technology-based operating model is compared to traditional R&D methods.
Market marginality as a whole
Gain Therapeutics is working to discover new drugs using its proprietary technology platform to identify previously inaccessible targets. This graph shows average profitability, and Gain Therapeutics offers a new way to discover drugs. Their future profitability depends on the success of their platform and partnerships.
Employees in the company, segment and market as a whole
Number of employees in the company Gain Therapeutics Inc.
Gain Therapeutics uses its technology platform to discover new drugs for rare genetic and neurodegenerative diseases. Its team, visible in this graph, is primarily comprised of scientists. The size of its staff is an indicator of the intensity of its research and development activities.
Share of the company's employees Gain Therapeutics Inc. within the market segment - Treatment
Gain Therapeutics uses its technology platform to discover new drugs for rare genetic and neurodegenerative diseases. This chart shows the percentage of all scientists in this cutting-edge field that Gain attracts. This reflects its scientific potential and innovative approach to drug discovery using computational biology.
Number of employees in the market segment - Treatment
Gain Therapeutics is a biotech company using its platform to discover new drugs targeting misfolded proteins. Its staff consists of highly qualified scientists. The graph shows the team's growth, which directly reflects progress in preclinical studies and validation of its innovative technology platform.
Number of employees in the market as a whole
Gain Therapeutics uses AI technologies to develop new drugs. This is at the cutting edge of biotech, where hiring dynamics are driven not by the overall market situation, but by the speed of discovery. This chart provides a general overview, but for Gain, proving the effectiveness of its platform to attract investment is more important.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Gain Therapeutics Inc. (GANX)
Gain Therapeutics uses AI to create new drugs. It combines biotech and IT. This chart shows that the market values its platform highly. The high market capitalization per employee speaks to the synergy between two highly research-intensive industries and their enormous potential.
%20of%20the%20company%20Gain%20Therapeutics%20Inc.%20(GANX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Gain-Therapeutics-Inc.-GANX&v=1772647244272 "Chart of market capitalization per employee (in thousands of dollars) of the company Gain Therapeutics Inc. (GANX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Treatment
Gain Therapeutics, Inc. uses its proprietary technology platform to discover new drugs for rare genetic and neurodegenerative diseases. The company's value is determined by the potential of its platform. This chart shows the premium investors place on this innovative approach to drug development per scientist.
%20by%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Treatment&v=1772647244293 "Market capitalization per employee (in thousands of dollars) by market segment - Treatment")
Market capitalization per employee (in thousands of dollars) for the overall market
Gain Therapeutics uses its technology platform to discover new drugs for rare genetic and neurodegenerative diseases. It is a discovery-stage biotech. The chart shows a high valuation per employee, as investors believe in the company's platform's potential to discover new therapeutic targets, which is the core value creation in biotech.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772647244355 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Gain Therapeutics Inc. (GANX)
Gain Therapeutics is a biopharmaceutical company using its proprietary platform (SEE-Tx) to discover and develop small molecules targeting complex proteins. This is an R&D business. This chart shows the R&D capital burn per scientist. This represents investment in the technology platform for drug discovery.
%20Chart%20Gain%20Therapeutics%20Inc.%20(GANX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Gain-Therapeutics-Inc.-GANX&v=1772647244374 "Company Profit Per Employee (in thousands of dollars) Chart Gain Therapeutics Inc. (GANX)")
Profit per employee (in thousands of dollars) in the market segment - Treatment
Gain Therapeutics (GANX) is a biotech company using its proprietary platform to discover new drugs aimed at restoring the function of misfolded proteins. It is an early-stage R&D company. This chart shows how effectively their research team and platform (their core asset) utilize capital to generate future intellectual property.
%20in%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Treatment&v=1772647244405 "Chart of profit per employee (in thousands of dollars) in the market segment - Treatment")
Profit per employee (in thousands of dollars) for the market as a whole
Gain Therapeutics is a biotech company using AI to discover new drugs (primarily for rare diseases). It's a hybrid of IT and biotech. This chart shows the per-employee cost, which is typical for R&D. However, unlike traditional biotech, Gain Therapeutics' personnel costs include not only biologists but also data scientists, whose work is designed to accelerate molecule discovery.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772647244440 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Gain Therapeutics Inc. (GANX)
Gain Therapeutics is a biotech company using its platform to discover new drugs for rare genetic and neurodegenerative diseases. During the research phase, this graph is an indicator of future potential, not current sales. Any revenue per employee will likely come from strategic partnerships.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Gain-Therapeutics-Inc.-GANX&v=1772647244465 "Sales chart per company employee Gain Therapeutics Inc. (GANX)")
Sales per employee in the market segment - Treatment
Gain Therapeutics uses AI and its platform to discover new drugs aimed at restoring the function of misfolded proteins. This graph shows the average revenue per employee in the sector. This is a benchmark for biotech R&D. It demonstrates the level of productivity required in the industry to monetize such complex scientific platforms.
Sales per employee for the market as a whole
Gain Therapeutics, Inc. (GANX) is a biotech company using an AI platform to discover new drugs aimed at restoring the function of misfolded proteins (in Parkinson's disease). It is an R&D company. This graph shows the current (zero) commercial return per scientist.
Short shares by company, segment and market as a whole
Shares shorted by company Gain Therapeutics Inc. (GANX)
Gain Therapeutics is an early-stage biopharmaceutical company using AI to discover new drugs for rare genetic and neurodegenerative diseases. This is a highly risky field. The chart shows the number of investors betting that its platform will fail to generate successful candidates or that the path to clinical development will be too long and expensive.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Gain-Therapeutics-Inc.-GANX&v=1772647244526 "Short Shares Chart for the Company Gain Therapeutics Inc. (GANX)")
Shares shorted by market segment - Treatment
Gain Therapeutics uses AI to discover new drugs that target allosteric sites on proteins. It's a cutting-edge, but risky, approach. This chart reflects the bearish sentiment in the sector. It shows how skeptical investors are overall about new drug discovery platforms, expecting a long road to success.
Shares shorted by the overall market
Gain Therapeutics is searching for new treatments for complex diseases, a long and expensive process. This chart measures the overall risk appetite in the market. When fear prevails, investors lose patience with biotechs like GANX, which burn through capital for years before receiving FDA approval. The risk of failure becomes unacceptable.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Gain Therapeutics Inc. (GANX)
Gain Therapeutics uses AI to discover new treatments, primarily in neuroscience. As an early-stage biotech, its shares are susceptible to speculative price movements driven by development news. This indicator measures the strength of such movements. It shows when the stock is overheated (above 70) due to optimism or excessively oversold (below 30) due to delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Gain-Therapeutics-Inc.-GANX&v=1772647244645 "RSI 14 indicator chart for the company's stock Gain Therapeutics Inc. (GANX)")
RSI 14 Market Segment - Treatment
Gain Therapeutics (GANX) is a "biotech" company that specializes in protein repair. Their AI platform (SEE-Tx) searches for small molecules that "repair" (stabilize) misfolded proteins (the cause of Parkinson's disease). The "Treatment" (biotech) sector thrives on news. RSI\_14\_Seg shows the "temperature" of the entire segment. It helps us understand: is GANX's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Gain Therapeutics (GANX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GANX (Gain Therapeutics Inc.)
Gain Therapeutics (GANX) is a biotech company using an AI platform to identify new "allosteric" sites on proteins to treat genetic diseases. This chart shows the average target price. It reflects analysts' speculative valuation of this computing platform and its R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GANX-Gain-Therapeutics-Inc.&v=1772647244818 "A chart showing analyst consensus forecasts for the expected stock price. GANX (Gain Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price GANX (Gain Therapeutics Inc.)
Gain Therapeutics (GANX) is a biotech company using a computational platform to discover new small-molecule drugs for rare metabolic and neurodegenerative diseases. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GANX-Gain-Therapeutics-Inc.&v=1772647244904 "A chart showing the difference between the consensus forecast and the actual stock price. GANX (Gain Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Treatment
Gain Therapeutics is a biotech company using its AI platform (Site-Specific Targeting) to discover new drugs for neurodegenerative diseases (Parkinson's). This chart shows analysts' overall expectations for the treatment sector. It reflects whether experts believe AI can accelerate R&D in neuroscience.
Analysts' consensus forecast for the overall market share price
Gain is a clinical-stage biotech company specializing in neurological disorders. It's an R&D company that's burning cash. This chart, reflecting the market's overall risk appetite, is vital. When optimism is high, investors fund speculative science. When pessimism ("risk-off") takes over, funding for biotechs like GANX dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Gain Therapeutics Inc.
Gain Therapeutics is a biotech company using AI to discover new drugs. Their platform (SEE-Tx) uses supercomputers to find allosteric sites on proteins—hidden targets for treating diseases like Parkinson's. This chart is a clear indicator of faith in their AI platform. Its dynamics represent the market's speculative assessment of their R&D progress and their chances of a scientific breakthrough.
AKIMA Market Segment Index - Treatment
Gain Therapeutics (GANX) is a biotech company using its AI-powered platform to identify and develop new drugs (allosteric regulators) for the treatment of CNS diseases. The chart shows the average index for the segment, helping investors balance Gain's advanced technological approach with the high risk inherent in developing drugs for brain diseases.
The AKIM Index for the overall market
Gain Therapeutics is a biotech company using the SEE-Tx platform to discover allosteric molecules for the treatment of neurodegenerative diseases (Parkinson's). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this early-stage scientific story compares to overall economic trends.
